Results 151 to 160 of about 1,649,512 (376)
This study describes a T cell surface engineering strategy that integrates polymer materials with tumor immunology, aiming to achieve broad‐spectrum anti‐tumor applications of glycopolymer‐engineered T (G‐T) cells via non‐genetic modification. Glycopolymer engineering generally modulates immune‐tumor crosstalk through specific cell‐cell interactions ...
Lihua Yao +8 more
wiley +1 more source
B. C. G. plus recombinant interferon α2b in superficial bladder cancer
We have studied the efficacy of adjuvant therapy in the form of low dose B.C.G. and interferon alpha 2b. In the present study 7patients with superficial bladder car-cinoma (6 recurrent and I primary) have been treated by TURBT and intravesical ...
Gyan Prakash Singh +3 more
doaj
Triple‐negative breast cancer exhibits variable sensitivity to PRMT5 inhibition. Basal interferon signaling is identified as a key biomarker of response. PARP inhibition with olaparib induces IFN signaling, sensitizing resistant TNBC cells to PRMT5 inhibitors.
Ziwen Zhang +9 more
wiley +1 more source
Human MxA Protein Protects Mice Lacking a Functional Alpha/Beta Interferon System against La Crosse Virus and Other Lethal Viral Infections [PDF]
Hans Peter Hefti +6 more
openalex +1 more source
Glycosylation, specifically hypersialylation, is identified as a critical factor in human intervertebral disc (IVD) degeneration—a major cause of low back pain. This study demonstrates that inhibiting sialylation reduces inflammation and oxidative stress in IVD tissues, suggesting new therapeutic possibilities.
Kieran Joyce +8 more
wiley +1 more source
Role of MxB in Alpha Interferon-Mediated Inhibition of HIV-1 Infection. [PDF]
Xu B, Pan Q, Liang C.
europepmc +1 more source
Intensive chemotherapy induction followed by interferon-alpha maintenance in patients with Philadelphia chromosome-positive chronic myelogenous leukemia [PDF]
Hagop M. Kantarjian +8 more
openalex +1 more source
This study presents an engineered human interferon‐lambda (hIFN‐λ) as an intranasal prophylactic against respiratory viruses. By combining AI‐guided backbone redesign and glycoengineering, the authors developed a thermostable, protease‐resistant, and scalable variant with improved mucosal penetration.
Jeongwon Yun +12 more
wiley +1 more source

